Genetic heterogeneity and clonal evolution in neuroblastoma - PubMed (original) (raw)
Genetic heterogeneity and clonal evolution in neuroblastoma
J Mora et al. Br J Cancer. 2001.
Free PMC article
Abstract
Tumour heterogeneity and clonal evolution at the genetic level may explain the development of malignant or resistant disease during clinical progression of neuroblastoma (NB). In this report we use 1p allelic analysis and DNA ploidy to evaluate clonal heterogeneity and clonal selection in vivo. We studied a total of 69 tumours from 29 patients with NB. To evaluate tumour heterogeneity and clonal evolution in vivo we used a panel of polymorphic allelic markers mapping to chromosome 1. 33 tumours from 12 patients (group 1) were obtained from different sites during the same surgery or at sequential surgeries without intervening chemotherapy to evaluate genetic heterogeneity. Paired samples from 10 patients (group 2) were used to evaluate clonal selection before and after chemotherapy. In 6 cases paired tumours and derived cell lines were studied. Analysis of DNA ploidy changes by karyotype, FISH and flow cytometry was performed in 15 tumours from 6 multiply recurred local-regional (LR) NB patients. Allelotype study revealed that 66% (8/12) of group 1 samples were heterogeneous, with distinct allelic patterns in tumour samples separated by time or location. In group 2 allelic patterns were different in post-chemotherapy specimens in 60% (6/10). DNA ploidy analysis showed that pre-chemotherapy samples contained 2 distinct ploidy clones, one diploid and one triploid, whereas all post-chemotherapy tumor samples were 100% diploid. These findings suggest that NB exhibits a high degree of clonal heterogeneity and clonal evolution occurs during the course of therapy and clinical progression.
Similar articles
- Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma.
Mora J, Lavarino C, Alaminos M, Cheung NK, Ríos J, de Torres C, Illei P, Juan G, Gerald WL. Mora J, et al. Genes Chromosomes Cancer. 2007 Apr;46(4):385-96. doi: 10.1002/gcc.20421. Genes Chromosomes Cancer. 2007. PMID: 17243159 - Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas.
Bonsing BA, Devilee P, Cleton-Jansen AM, Kuipers-Dijkshoorn N, Fleuren GJ, Cornelisse CJ. Bonsing BA, et al. Cancer Res. 1993 Aug 15;53(16):3804-11. Cancer Res. 1993. PMID: 8101767 - Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss.
Hoshi M, Otagiri N, Shiwaku HO, Asakawa S, Shimizu N, Kaneko Y, Ohi R, Hayashi Y, Horii A. Hoshi M, et al. Br J Cancer. 2000 Jun;82(11):1801-7. doi: 10.1054/bjoc.2000.1108. Br J Cancer. 2000. PMID: 10839294 Free PMC article. - Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.
Mora J, Gerald WL, Cheung NK. Mora J, et al. Cancer Lett. 2003 Jul 18;197(1-2):119-24. doi: 10.1016/s0304-3835(03)00094-6. Cancer Lett. 2003. PMID: 12880970 Review. - [Utilization of MLPA to detection of genetic changes in neuroblastoma].
Vícha A, Eckschlager T. Vícha A, et al. Klin Onkol. 2008;21(4):149-53. Klin Onkol. 2008. PMID: 19102220 Review. Czech.
Cited by
- Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation.
Jiang P, Zhang T, Wu B, Li X, Fu M, Xu B. Jiang P, et al. Med Oncol. 2023 Oct 16;40(11):332. doi: 10.1007/s12032-023-02199-z. Med Oncol. 2023. PMID: 37843625 - FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P, Huang M, Qi W, Wang F, Yang T, Gao T, Luo C, Deng J, Yang Z, Zhou T, Zou Y, Gao G, Yang X. Jiang P, et al. J Exp Clin Cancer Res. 2019 Sep 11;38(1):400. doi: 10.1186/s13046-019-1414-6. J Exp Clin Cancer Res. 2019. PMID: 31511046 Free PMC article. - Intratumor and Intertumor Heterogeneity in Melanoma.
Grzywa TM, Paskal W, Włodarski PK. Grzywa TM, et al. Transl Oncol. 2017 Dec;10(6):956-975. doi: 10.1016/j.tranon.2017.09.007. Epub 2017 Oct 24. Transl Oncol. 2017. PMID: 29078205 Free PMC article. Review. - Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Bosse KR, Maris JM. Bosse KR, et al. Cancer. 2016 Jan 1;122(1):20-33. doi: 10.1002/cncr.29706. Epub 2015 Nov 5. Cancer. 2016. PMID: 26539795 Free PMC article. Review. - Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer.
Ferreira-Facio CS, Milito C, Botafogo V, Fontana M, Thiago LS, Oliveira E, da Rocha-Filho AS, Werneck F, Forny DN, Dekermacher S, de Azambuja AP, Ferman SE, de Faria PA, Land MG, Orfao A, Costa ES. Ferreira-Facio CS, et al. PLoS One. 2013;8(3):e55534. doi: 10.1371/journal.pone.0055534. Epub 2013 Mar 5. PLoS One. 2013. PMID: 23472067 Free PMC article.
References
- Cancer Res. 1997 Sep 15;57(18):4082-90 - PubMed
- J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):176-7 - PubMed
- Cancer. 1999 Jul 15;86(2):349-63 - PubMed
- Cancer. 2001 Jan 15;91(2):435-42 - PubMed
- J Mol Diagn. 2000 Feb;2(1):37-46 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical